Patients with detectable IL-6 had significantly lower albumin (detectable IL-6, 3.3 ± 0.5 vs. undetectable IL-6, 3.7 ± 0.6, P < 0.001), higher bilirubin (1.6 ± 1.5 vs. 1.2 ± 0.8, P = 0.006), and higher Model for End-stage Liver Disease (MELD) scores (11 ± 3 vs. 9 ± 2, P < 0.001) than patients with undetectable IL-6. Here, ALB is linked to End Stage Liver Disease.